"10.1371_journal.pmed.0050166","plos medicine","2008-08-12T00:00:00Z","Sylvain Rheims; Michel Cucherat; Alexis Arzimanoglou; Philippe Ryvlin","Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon, France; CTRS INSERM-IDEE, Institute for Children and Adolescents with Epilepsy, Hospices Civils de Lyon, Lyon, France; Department of Clinical Pharmacology, EA 643, Lyon-1 University, Laennec Faculty of Medicine, Lyon, France; Department of Epileptology, Sleep and Pediatric Neurophysiology, Hospices Civils de Lyon, Lyon, France; INSERM U821, Lyon, France","none","SR has received speaker fees from Pfizer. MC has no conflict of interest. AA has received speaker or consultant fees from Pfizer, Sanofi-Aventis, GlaxoSmithKline (GSK), Jansen-Cilag, UCB Pharma, EISAI, and Valeant. PR has received speaker fees from Cyberonics, Eisai, GSK, Janssen-Cilag, Novartis, Pfizer, Sanofi-Synthelabo, and UCB; and consultant fees from Cyberonics, GSK, Janssen-Cilag, Novartis, Pfizer, UCB, and Valeant.","2008","08","Sylvain Rheims","SR",4,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
